Participants were randomized to receive 3 mg, 7 mg, or 14 mg of oral semaglutide or 100 mg of sitagliptin once daily
Semaglutide is a GLP-1 receptor agonist that works by slowing stomach emptying and signaling fullness to your brain, with clinical trials showing average weight loss of 15% over 68 weeks
Typically, Mounjaro is available to individuals with a BMI of 30 or higher , or those with a BMI of 25 or higher if they also have weight-related health concerns, such as type 2 diabetes
Fatigue that worsens over weeks, appears independent of dose changes, or coexists with unusual symptoms may indicate anemia, thyroid dysfunction, or other medical conditions
A robust status page and transparent incident reports also signal respect for the users time
Discuss with your healthcare provider before using NSAIDs